Evolution of MS Treatments
Henrik Ahvenjarvi, MD, PhD student from the University of Oulu, conducted a retrospective study, along with his team, on the evolution of initial disease-modifying treatments for relapse remitting multiple sclerosis in Finland from 2013 to 2022. Among others, the study showed an increase in high efficacy treatments from 7% to 44%, with a decrease in medium efficacy treatments. Watch the MEDtalk and find out more.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
